Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1998-07-17

AUTHORS

R Gum, J Juarez, H Allgayer, A Mazar, Y Wang, D Boyd

ABSTRACT

The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA. Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5 min) increase in JNK activity. Maximal JNK activity (12-fold induction) occurred after 30 min; this preceding the earliest detected rise in u-PAR protein (2 h). Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (−184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays. PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain. The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1. Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid. We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1. Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression. More... »

PAGES

213-225

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.onc.1201917

DOI

http://dx.doi.org/10.1038/sj.onc.1201917

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017347102

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9674706


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium-Calmodulin-Dependent Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flavonoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "JNK Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nerve Tissue Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Promoter Regions, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein-Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-raf", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Cell Surface", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Urokinase Plasminogen Activator", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetradecanoylphorbol Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription Factor AP-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Up-Regulation", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gum", 
        "givenName": "R", 
        "id": "sg:person.01077711452.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077711452.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Juarez", 
        "givenName": "J", 
        "id": "sg:person.01017445730.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017445730.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allgayer", 
        "givenName": "H", 
        "id": "sg:person.01014122003.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014122003.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mazar", 
        "givenName": "A", 
        "id": "sg:person.01072434141.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072434141.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Y", 
        "id": "sg:person.0747064230.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747064230.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyd", 
        "givenName": "D", 
        "id": "sg:person.01145207075.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145207075.25"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-07-17", 
    "datePublishedReg": "1998-07-17", 
    "description": "The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA. Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5\u2009min) increase in JNK activity. Maximal JNK activity (12-fold induction) occurred after 30\u2009min; this preceding the earliest detected rise in u-PAR protein (2\u2009h). Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (\u2212184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays. PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain. The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1. Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid. We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1. Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.onc.1201917", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2440396", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2471333", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2490273", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097543", 
        "issn": [
          "0950-9232", 
          "1476-5594"
        ], 
        "name": "Oncogene", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "keywords": [
      "urokinase-type plasminogen activator receptor", 
      "PAR expression", 
      "OVCAR-3 ovarian cancer cells", 
      "dose-response study", 
      "Ha-ras", 
      "ovarian cancer cells", 
      "variety of tumors", 
      "low JNK activities", 
      "PAR promoter activity", 
      "plasminogen activator receptor (uPAR) expression", 
      "plasminogen activator receptor", 
      "JNK activity", 
      "PAR gene expression", 
      "ovarian cancer", 
      "urokinase-type plasminogen activator receptor (uPAR) expression", 
      "receptor expression", 
      "promoter activity", 
      "OVCAR-3 cells", 
      "stress-inducing stimuli", 
      "tumor progression", 
      "ability of PMA", 
      "concurrent stimulation", 
      "activator receptor", 
      "stimulation", 
      "cancer cells", 
      "protein levels", 
      "dependent stimulation", 
      "gene expression", 
      "luciferase reporter", 
      "PMA", 
      "phorbol ester", 
      "PMA treatment", 
      "signaling mechanism", 
      "current study", 
      "cells", 
      "expression", 
      "previous studies", 
      "AP-1 motif", 
      "activity", 
      "JNK1", 
      "dominant negative MEKK1", 
      "tumors", 
      "cancer", 
      "study", 
      "biological significance", 
      "progression", 
      "upstream activator", 
      "receptors", 
      "expression constructs", 
      "treatment", 
      "rapid increase", 
      "expression vector", 
      "mobility shift assays", 
      "cascade", 
      "induction", 
      "activation", 
      "genes", 
      "oncogene", 
      "effect", 
      "stimuli", 
      "min", 
      "assays", 
      "caution", 
      "shift assays", 
      "transfection", 
      "inducible gene expression", 
      "activator", 
      "pathway", 
      "GAL4 DNA-binding domain", 
      "dominant negative expression constructs", 
      "levels", 
      "significance", 
      "PAR protein levels", 
      "DNA-binding domain", 
      "Jun transactivation domain", 
      "individual expression", 
      "increase", 
      "protein", 
      "inductive effect", 
      "regulation", 
      "transactivation domain", 
      "reporter", 
      "signaling modules", 
      "active MEKK1", 
      "high activity", 
      "Rac-1", 
      "mechanism", 
      "PAR proteins", 
      "MEKK1", 
      "plasmid", 
      "JNK1-dependent", 
      "alternate possibilities", 
      "ability", 
      "data", 
      "inclusion", 
      "rise", 
      "esters", 
      "variety", 
      "possibility", 
      "motif", 
      "constructs", 
      "domain", 
      "vector", 
      "trans", 
      "module", 
      "Raf-1-ERK", 
      "PAR-deficient OVCAR-3 ovarian cancer cells", 
      "Maximal JNK activity", 
      "intact upstream AP-1 motif", 
      "upstream AP-1 motif", 
      "Jun trans", 
      "GAL4-regulated luciferase reporter", 
      "kinase-defective JNK1", 
      "negative MEKK1", 
      "kinase-defective JNK1 plasmid", 
      "JNK1 plasmid", 
      "negative expression constructs", 
      "JNK1-independent", 
      "linear signaling modules", 
      "activator receptor expression"
    ], 
    "name": "Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules", 
    "pagination": "213-225", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017347102"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.onc.1201917"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9674706"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.onc.1201917", 
      "https://app.dimensions.ai/details/publication/pub.1017347102"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_280.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.onc.1201917"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'


 

This table displays all metadata directly associated to this object as RDF triples.

304 TRIPLES      21 PREDICATES      164 URIs      155 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.onc.1201917 schema:about N0c3441967b2f4e0e8407e38fd2e29b8c
2 N196bfdd4cd254d1a9dd235790f3d7e0e
3 N34901603e7c34af7af318c8a0ec84d46
4 N3db9096ab7c94fafb83b7f0e68c3a0d2
5 N4bf81561bbcf4e0eba3dd3f9726a183c
6 N5447788b38e44bb7aeb4e064a8b20376
7 N5cea24b621304348aec24f578c172bb7
8 N6bbf5a0db45146c2b9da9fa713b0402e
9 N7243d98a859448fa902139d0b501e57a
10 N7bc1cd19dd8c4c0e80a97a17b677cf51
11 N7d9b716660f3425ab249b2966f18dce3
12 N83a05275ac6c47368886124ef2a23a70
13 N8b5e02bae5e5458a98cd11336cd13a08
14 N99220311cd4e438cb0415b1e4b38231d
15 Nbcd4165364ae4f5fb1faab3249cbffd9
16 Nd1a2dc61350747c9a560d23c2fccc9f4
17 Nf1bb8e03e5094c4bb4a71b9e35f21d3f
18 anzsrc-for:11
19 anzsrc-for:1103
20 anzsrc-for:1112
21 schema:author Nc4bd0c6711d24eae8097cba8cb437763
22 schema:datePublished 1998-07-17
23 schema:datePublishedReg 1998-07-17
24 schema:description The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA. Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5 min) increase in JNK activity. Maximal JNK activity (12-fold induction) occurred after 30 min; this preceding the earliest detected rise in u-PAR protein (2 h). Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (−184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays. PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain. The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1. Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid. We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1. Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N02990e6effe3425785da9f86cf4e61f6
29 Nc6f145e2510f410e9e6cc7acb0fd547f
30 sg:journal.1097543
31 schema:keywords AP-1 motif
32 DNA-binding domain
33 GAL4 DNA-binding domain
34 GAL4-regulated luciferase reporter
35 Ha-ras
36 JNK activity
37 JNK1
38 JNK1 plasmid
39 JNK1-dependent
40 JNK1-independent
41 Jun trans
42 Jun transactivation domain
43 MEKK1
44 Maximal JNK activity
45 OVCAR-3 cells
46 OVCAR-3 ovarian cancer cells
47 PAR expression
48 PAR gene expression
49 PAR promoter activity
50 PAR protein levels
51 PAR proteins
52 PAR-deficient OVCAR-3 ovarian cancer cells
53 PMA
54 PMA treatment
55 Rac-1
56 Raf-1-ERK
57 ability
58 ability of PMA
59 activation
60 activator
61 activator receptor
62 activator receptor expression
63 active MEKK1
64 activity
65 alternate possibilities
66 assays
67 biological significance
68 cancer
69 cancer cells
70 cascade
71 caution
72 cells
73 concurrent stimulation
74 constructs
75 current study
76 data
77 dependent stimulation
78 domain
79 dominant negative MEKK1
80 dominant negative expression constructs
81 dose-response study
82 effect
83 esters
84 expression
85 expression constructs
86 expression vector
87 gene expression
88 genes
89 high activity
90 inclusion
91 increase
92 individual expression
93 inducible gene expression
94 induction
95 inductive effect
96 intact upstream AP-1 motif
97 kinase-defective JNK1
98 kinase-defective JNK1 plasmid
99 levels
100 linear signaling modules
101 low JNK activities
102 luciferase reporter
103 mechanism
104 min
105 mobility shift assays
106 module
107 motif
108 negative MEKK1
109 negative expression constructs
110 oncogene
111 ovarian cancer
112 ovarian cancer cells
113 pathway
114 phorbol ester
115 plasmid
116 plasminogen activator receptor
117 plasminogen activator receptor (uPAR) expression
118 possibility
119 previous studies
120 progression
121 promoter activity
122 protein
123 protein levels
124 rapid increase
125 receptor expression
126 receptors
127 regulation
128 reporter
129 rise
130 shift assays
131 signaling mechanism
132 signaling modules
133 significance
134 stimulation
135 stimuli
136 stress-inducing stimuli
137 study
138 trans
139 transactivation domain
140 transfection
141 treatment
142 tumor progression
143 tumors
144 upstream AP-1 motif
145 upstream activator
146 urokinase-type plasminogen activator receptor
147 urokinase-type plasminogen activator receptor (uPAR) expression
148 variety
149 variety of tumors
150 vector
151 schema:name Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules
152 schema:pagination 213-225
153 schema:productId N4a0043f8bd3945419c1f3598cd7c59e1
154 N6c6941322dbb432fb4a4607e37262e95
155 Nf0ad0428613747fa801fbd4218c0c2f6
156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017347102
157 https://doi.org/10.1038/sj.onc.1201917
158 schema:sdDatePublished 2021-12-01T19:09
159 schema:sdLicense https://scigraph.springernature.com/explorer/license/
160 schema:sdPublisher Ncf8a4c0647fb4198ac1c9ceb968a56fc
161 schema:url https://doi.org/10.1038/sj.onc.1201917
162 sgo:license sg:explorer/license/
163 sgo:sdDataset articles
164 rdf:type schema:ScholarlyArticle
165 N02990e6effe3425785da9f86cf4e61f6 schema:volumeNumber 17
166 rdf:type schema:PublicationVolume
167 N06fef6dbd9e5439aadc9ad5fd7b847f8 rdf:first sg:person.0747064230.39
168 rdf:rest Na96ea22e09a64b7ea97c7906e4f823ec
169 N0c3441967b2f4e0e8407e38fd2e29b8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Promoter Regions, Genetic
171 rdf:type schema:DefinedTerm
172 N196bfdd4cd254d1a9dd235790f3d7e0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Dose-Response Relationship, Drug
174 rdf:type schema:DefinedTerm
175 N2ebd97c89ef2490c8902d4dd61172045 rdf:first sg:person.01017445730.26
176 rdf:rest N8d4a870abc0b4792a8dadbc6a837c3cd
177 N34901603e7c34af7af318c8a0ec84d46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Up-Regulation
179 rdf:type schema:DefinedTerm
180 N3db9096ab7c94fafb83b7f0e68c3a0d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Nerve Tissue Proteins
182 rdf:type schema:DefinedTerm
183 N4a0043f8bd3945419c1f3598cd7c59e1 schema:name pubmed_id
184 schema:value 9674706
185 rdf:type schema:PropertyValue
186 N4bf81561bbcf4e0eba3dd3f9726a183c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Calcium-Calmodulin-Dependent Protein Kinases
188 rdf:type schema:DefinedTerm
189 N5447788b38e44bb7aeb4e064a8b20376 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name JNK Mitogen-Activated Protein Kinases
191 rdf:type schema:DefinedTerm
192 N5cea24b621304348aec24f578c172bb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Signal Transduction
194 rdf:type schema:DefinedTerm
195 N6bbf5a0db45146c2b9da9fa713b0402e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Mitogen-Activated Protein Kinases
197 rdf:type schema:DefinedTerm
198 N6c6941322dbb432fb4a4607e37262e95 schema:name doi
199 schema:value 10.1038/sj.onc.1201917
200 rdf:type schema:PropertyValue
201 N7243d98a859448fa902139d0b501e57a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Flavonoids
203 rdf:type schema:DefinedTerm
204 N7bc1cd19dd8c4c0e80a97a17b677cf51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Transcription Factor AP-1
206 rdf:type schema:DefinedTerm
207 N7d9b716660f3425ab249b2966f18dce3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Transcription, Genetic
209 rdf:type schema:DefinedTerm
210 N83a05275ac6c47368886124ef2a23a70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Receptors, Urokinase Plasminogen Activator
212 rdf:type schema:DefinedTerm
213 N8b5e02bae5e5458a98cd11336cd13a08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Receptors, Cell Surface
215 rdf:type schema:DefinedTerm
216 N8d4a870abc0b4792a8dadbc6a837c3cd rdf:first sg:person.01014122003.46
217 rdf:rest Nb87fce39ea1e41969f294c7d6e872edf
218 N99220311cd4e438cb0415b1e4b38231d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Tetradecanoylphorbol Acetate
220 rdf:type schema:DefinedTerm
221 Na96ea22e09a64b7ea97c7906e4f823ec rdf:first sg:person.01145207075.25
222 rdf:rest rdf:nil
223 Nb87fce39ea1e41969f294c7d6e872edf rdf:first sg:person.01072434141.27
224 rdf:rest N06fef6dbd9e5439aadc9ad5fd7b847f8
225 Nbcd4165364ae4f5fb1faab3249cbffd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Protein-Serine-Threonine Kinases
227 rdf:type schema:DefinedTerm
228 Nc4bd0c6711d24eae8097cba8cb437763 rdf:first sg:person.01077711452.40
229 rdf:rest N2ebd97c89ef2490c8902d4dd61172045
230 Nc6f145e2510f410e9e6cc7acb0fd547f schema:issueNumber 2
231 rdf:type schema:PublicationIssue
232 Ncf8a4c0647fb4198ac1c9ceb968a56fc schema:name Springer Nature - SN SciGraph project
233 rdf:type schema:Organization
234 Nd1a2dc61350747c9a560d23c2fccc9f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Proto-Oncogene Proteins c-raf
236 rdf:type schema:DefinedTerm
237 Nf0ad0428613747fa801fbd4218c0c2f6 schema:name dimensions_id
238 schema:value pub.1017347102
239 rdf:type schema:PropertyValue
240 Nf1bb8e03e5094c4bb4a71b9e35f21d3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
241 schema:name Proto-Oncogene Proteins p21(ras)
242 rdf:type schema:DefinedTerm
243 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
244 schema:name Medical and Health Sciences
245 rdf:type schema:DefinedTerm
246 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
247 schema:name Clinical Sciences
248 rdf:type schema:DefinedTerm
249 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
250 schema:name Oncology and Carcinogenesis
251 rdf:type schema:DefinedTerm
252 sg:grant.2440396 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1201917
253 rdf:type schema:MonetaryGrant
254 sg:grant.2471333 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1201917
255 rdf:type schema:MonetaryGrant
256 sg:grant.2490273 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1201917
257 rdf:type schema:MonetaryGrant
258 sg:journal.1097543 schema:issn 0950-9232
259 1476-5594
260 schema:name Oncogene
261 schema:publisher Springer Nature
262 rdf:type schema:Periodical
263 sg:person.01014122003.46 schema:affiliation grid-institutes:grid.240145.6
264 schema:familyName Allgayer
265 schema:givenName H
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014122003.46
267 rdf:type schema:Person
268 sg:person.01017445730.26 schema:affiliation grid-institutes:grid.240145.6
269 schema:familyName Juarez
270 schema:givenName J
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017445730.26
272 rdf:type schema:Person
273 sg:person.01072434141.27 schema:affiliation grid-institutes:None
274 schema:familyName Mazar
275 schema:givenName A
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072434141.27
277 rdf:type schema:Person
278 sg:person.01077711452.40 schema:affiliation grid-institutes:grid.418019.5
279 schema:familyName Gum
280 schema:givenName R
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077711452.40
282 rdf:type schema:Person
283 sg:person.01145207075.25 schema:affiliation grid-institutes:grid.240145.6
284 schema:familyName Boyd
285 schema:givenName D
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145207075.25
287 rdf:type schema:Person
288 sg:person.0747064230.39 schema:affiliation grid-institutes:grid.1013.3
289 schema:familyName Wang
290 schema:givenName Y
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747064230.39
292 rdf:type schema:Person
293 grid-institutes:None schema:alternateName Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA
294 schema:name Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA
295 rdf:type schema:Organization
296 grid-institutes:grid.1013.3 schema:alternateName Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia
297 schema:name Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia
298 rdf:type schema:Organization
299 grid-institutes:grid.240145.6 schema:alternateName Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA
300 schema:name Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA
301 rdf:type schema:Organization
302 grid-institutes:grid.418019.5 schema:alternateName Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA
303 schema:name Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA
304 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...